{"id":10328,"date":"2025-01-16T11:30:00","date_gmt":"2025-01-16T06:00:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=10328"},"modified":"2025-02-12T15:15:47","modified_gmt":"2025-02-12T09:45:47","slug":"acute-kidney-injury-treatment-pipeline","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-pipeline","title":{"rendered":"What Does the Future Hold for Acute Kidney Injury? A Deep Dive into the Evolving Pipeline"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d16f0b6584d\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d16f0b6584d\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-pipeline\/#Acute_Kidney_Injury_Pipeline_Analysis\" >Acute Kidney Injury Pipeline Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-pipeline\/#MOAs_explored\" >MOAs explored<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-pipeline\/#Key_Companies_and_Their_Lead_Assets\" >Key Companies and Their Lead Assets<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-pipeline\/#Conclusion\" >Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong>Acute Kidney Injury <\/strong>is defined as a sudden advent of kidney failure or damage due to the accumulation of waste products in the bloodstream resulting in improper fluid outflow. It is profoundly evident in elderly patients who are hospitalized, especially in intensive care units. The reported incident cases range from <strong>22% to 67% <\/strong>of admissions. The indication is widely associated with an array of organs that get affected, such as coronary heart disease, chronic kidney disease, diabetes, etc. It emerges as an ailment in about <strong>5\u201330% <\/strong>of patients who undergo cardiothoracic surgery, based on the definition used for AKI. If AKI appears after major abdominal surgery, the risk of death is markedly increased (over 12-fold). Besides, it is worth noting that AKI occurs due to several clinical manifestations as well, such as sepsis, cardiac catheterization, and cardiac surgery, which are mostly hospital-acquired.<\/p>\n\n\n\n<p>The significant unmet need that encompasses AKI is that currently, neither there are any proven therapeutic strategies to reduce post-AKI sequelae nor affirmed robust evidence to date to inform strategy for the provision of health care. Moreover, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-kidney-injury-aki-market\">Acute kidney injury market<\/a> does not hold any approved therapy to treat it specifically, which also adds to its shortcomings.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-acute-kidney-injury-pipeline-analysis\"><span class=\"ez-toc-section\" id=\"Acute_Kidney_Injury_Pipeline_Analysis\"><\/span>Acute Kidney Injury Pipeline Analysis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-kidney-injury-aki-pipeline-insight\">Acute Kidney Injury pipeline<\/a> is witnessing promising developments, with various novel therapies emerging to target different underlying causes and risk factors for AKI. The increasing focus is on preventing AKI in high-risk patient groups, particularly those undergoing cardiac surgery, suffering from sepsis, or experiencing hepatic renal syndrome (HRS). These patient populations are particularly vulnerable, and current treatments do not adequately address the growing unmet need for effective prevention and treatment options. As the number of people affected by AKI continues to rise, the market for its treatments is expected to expand significantly during the forecast period from 2024 to 2034.<\/p>\n\n\n\n<p>The emerging pipeline for AKI consists of several promising candidates aimed at providing novel therapeutic approaches for treating AKI in various high-risk settings. These include drugs designed to target AKI associated with comorbidities such as sepsis, cardiac surgery, delayed graft function, and more. There are approximately <strong>30+ companies<\/strong> and <strong>30+ pipeline drugs<\/strong> in the Acute Kidney Injury pipeline landscape. Some key players in the AKI pipeline include <strong>Renibus Therapeutics, Ocelot Bio, AM-Pharma, Guard Therapeutics, <\/strong>and others. These companies are actively developing therapies to address the critical unmet needs of AKI patients, with the potential to reduce mortality rates and improve prognosis in hospital settings.<\/p>\n\n\n\n<p>Notable drugs currently under investigation in the pipeline include <strong>RBT-1, OCE-205, APX-115, Ilofotase alfa, and bRESCAP, <\/strong>among others. These candidates focus on different mechanisms, including addressing renal injury caused by systemic inflammation, oxidative stress, and ischemia-reperfusion, which are common in hospital-acquired AKI. The potential to develop more targeted, effective treatments could revolutionize AKI management, significantly improving patient outcomes.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"396\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16093814\/Acute-Kidney-Injury-Market-Size-and-key-players-2023-1024x396.png\" alt=\"\" class=\"wp-image-30802\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16093814\/Acute-Kidney-Injury-Market-Size-and-key-players-2023-1024x396.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16093814\/Acute-Kidney-Injury-Market-Size-and-key-players-2023-300x116.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16093814\/Acute-Kidney-Injury-Market-Size-and-key-players-2023-150x58.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16093814\/Acute-Kidney-Injury-Market-Size-and-key-players-2023-768x297.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16093814\/Acute-Kidney-Injury-Market-Size-and-key-players-2023-1536x595.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16093814\/Acute-Kidney-Injury-Market-Size-and-key-players-2023-2048x793.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Several well-established pharmaceutical companies are also investing heavily in AKI drug development, including <strong>Alexion Pharmaceuticals, Alloksys Life Sciences, AM-Pharma, AptaBio Therapeutics, Arch Biopartners, Guard Therapeutics, Novartis Pharmaceuticals, Ocelot Bio, Rediscovery Life Sciences, Renibus Therapeutics, and River 2 Renal.<\/strong> These companies, with their diverse portfolios, are expected to drive innovation in the AKI space and contribute to the anticipated market growth. With a range of promising therapies in the pipeline, the future of AKI treatment looks poised for significant progress.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-moas-explored\"><span class=\"ez-toc-section\" id=\"MOAs_explored\"><\/span>MOAs explored<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The mechanisms of action being explored in the AKI pipeline are diverse, including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Angiopoietin 1 Receptor Agonists:<\/strong> Four drugs are currently in preclinical development targeting this receptor, which plays a role in kidney repair and regeneration.<\/li>\n\n\n\n<li><strong>Alkaline Phosphatase Modulation: <\/strong>This MOA reduces inflammation and promotes kidney recovery.<\/li>\n\n\n\n<li><strong>Cell Therapy Applications:<\/strong> Several companies are investigating cellular therapies to repair damaged renal tissues.<\/li>\n\n\n\n<li><strong>Stem Cell Modulators: <\/strong>These drugs enhance kidney regeneration through stem cell mechanisms.<\/li>\n\n\n\n<li><strong>Actin Modulators and Amyloid Inhibitors:<\/strong> These approaches target cellular processes involved in kidney injury and inflammation.<\/li>\n<\/ul>\n\n\n\n<p>The exploration of these various MOAs indicates a comprehensive effort to tackle the underlying causes of AKI.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-companies-and-their-lead-assets\"><span class=\"ez-toc-section\" id=\"Key_Companies_and_Their_Lead_Assets\"><\/span>Key Companies and Their Lead Assets<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Renibus Therapeutics\u2019 RBT-1<\/strong> is an innovative investigational drug designed to activate anti-inflammatory, antioxidant, and iron-scavenging pathways, initiating a cytoprotective preconditioning response. <strong>RBT-1<\/strong> aims to reduce postoperative complications and improve recovery outcomes following cardiothoracic surgery by providing broad organ protection. With its potential to significantly enhance both short- and long-term patient recovery, <strong>RBT-1<\/strong> received <strong>Breakthrough Therapy Designation (BTD)<\/strong> from the US FDA in July 2023. The pivotal Phase III PROTECT trial, which began in October 2023, is expected to yield top-line results by mid-2025, with a potential <strong>New Drug Application (NDA)<\/strong> filing planned for early 2026. This marks a significant milestone in the <strong>acute kidney injury therapeutic market<\/strong>, offering hope for innovative <strong>acute kidney injury therapies<\/strong>.<\/p>\n\n\n\n<p><strong>Ocelot Bio\u2019s OCE-205<\/strong> is a novel therapeutic peptide designed to address <strong>end-stage<\/strong> <strong>liver<\/strong> <strong>disease<\/strong> <strong>(ESLD)<\/strong> complications, particularly <strong>hepatorenal syndrome (HRS)<\/strong>. By selectively targeting the vasopressin 1a (V1a) receptor and avoiding the vasopressin 2 (V2) receptor, <strong>OCE-205<\/strong> aims to reduce fluid retention and improve patient outcomes. Granted <strong>Orphan Drug Designation (ODD)<\/strong> by the FDA in August 2022, <strong>OCE-205<\/strong> is currently in Phase II clinical trials for patients with hepatorenal syndrome and acute kidney injury (HRS-AKI). Meanwhile, <strong>AptaBio Therapeutics\u2019 APX-115<\/strong>, a small-molecule inhibitor targeting NADPH-oxidase (NOX) isozymes, seeks to mitigate oxidative stress-related tissue damage. Approved for Phase II clinical trials by the FDA in January 2023, <strong>APX-115<\/strong> is under evaluation for <strong>contrast-induced acute kidney injury (CI-AKI)<\/strong>, with study completion anticipated by the end of 2024. These drugs represent key additions to the <strong>acute kidney injury pipeline<\/strong>, addressing unmet needs in <strong>acute kidney injury therapies<\/strong>.<\/p>\n\n\n\n<p><strong>AM Pharma\u2019s Ilofotase alfa<\/strong>, a recombinant alkaline phosphatase, offers a promising approach to mitigating kidney damage in <strong>sepsis-associated acute kidney injury (SA-AKI)<\/strong>. It showed significant mortality reduction in Phase II trials, leading to the ongoing <strong>REVIVAL Phase III trial<\/strong> across North America, Europe, and Japan. Despite challenges with its primary endpoint, the trial continues with interim analyses focusing on additional outcomes. A Phase I pharmacokinetics study in Japan further explores its safety and efficacy. These advancements underscore the dynamic progress in the <strong>therapeutic<\/strong> <strong>market<\/strong> of <strong>acute<\/strong> <strong>kidney<\/strong> <strong>injury, with a robust<\/strong> <strong>pipeline<\/strong> paving the way for transformative treatments.<\/p>\n\n\n\n<p>Explore the <strong>Future of AKI Treatment<\/strong>: Dive into <strong>Our Comprehensive Blog<\/strong> on the <a href=\"https:\/\/www.delveinsight.com\/blog\/breakthrough-therapies-acute-kidney-injury-treatment\" class=\"ek-link\"><strong><em>Latest Drugs in the Acute Kidney Injury Pipeline.<\/em><\/strong><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-kidney-injury-aki-market\"><strong>acute kidney injury therapeutic market<\/strong><\/a> is on the brink of transformative advancements, driven by a robust and dynamic pipeline of innovative therapies targeting diverse mechanisms of action. From cytoprotective preconditioning and oxidative stress inhibition to vasopressin receptor modulation and alkaline phosphatase therapies, these developments reflect an unwavering commitment to addressing the significant unmet needs in <strong>acute kidney injury treatment<\/strong>. The ongoing clinical trials and breakthrough designations for several key drugs underline the potential for paradigm-shifting progress in acute kidney injury therapies.<\/p>\n\n\n\n<p>As pharmaceutical leaders and biotech innovators continue to invest in <strong>acute kidney injury pipeline advancements<\/strong>, the future holds promise for more effective, targeted, and comprehensive solutions. These emerging therapies aim to improve survival rates and enhance long-term recovery and quality of life for patients. With increasing global attention and investment, the <strong>acute kidney injury therapeutic market<\/strong> is poised to redefine the standards of care, offering new hope to millions affected by this life-threatening condition.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-kidney-injury-aki-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16094026\/Acute-Kidney-Injury-Market-Outlook-1024x194.png\" alt=\"Acute Kidney Injury Market Outlook\" class=\"wp-image-30804\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16094026\/Acute-Kidney-Injury-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16094026\/Acute-Kidney-Injury-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16094026\/Acute-Kidney-Injury-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16094026\/Acute-Kidney-Injury-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16094026\/Acute-Kidney-Injury-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/16094026\/Acute-Kidney-Injury-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Acute Kidney Injury is defined as a sudden advent of kidney failure or damage due to the accumulation of waste products in the bloodstream resulting in improper fluid outflow. It is profoundly evident in elderly patients who are hospitalized, especially in intensive care units. The reported incident cases range from 22% to 67% of admissions. [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":30816,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[12850,15874,15876,15875,18570,18331,18324,2085,18325,18326,18329,18572,18574,18571,18575,18573],"industry":[17225],"therapeutic_areas":[17230],"class_list":["post-10328","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-acute-kidney-injury-market","tag-acute-kidney-injury-pipeline","tag-acute-kidney-injury-therapies","tag-aki","tag-alloksys","tag-am-pharma","tag-angion-biomedica","tag-astellas-pharma","tag-atox-bio","tag-exponential-biotherapies","tag-medibeacon","tag-pharming-technologies","tag-qpi-1002","tag-quark-pharmaceuticals","tag-ruconest","tag-teprasiran","industry-pharmaceutical","therapeutic_areas-genito-urinary-system-and-sex-hormones"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novel Insight Into Acute Kidney Injury Treatment Pipeline<\/title>\n<meta name=\"description\" content=\"The Acute Kidney Injury Therapies in the pipeline anticipated to launch in the next decade shall spur the AKI Market growth forward.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-pipeline\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novel Insight Into Acute Kidney Injury Treatment Pipeline\" \/>\n<meta property=\"og:description\" content=\"The Acute Kidney Injury Therapies in the pipeline anticipated to launch in the next decade shall spur the AKI Market growth forward.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-pipeline\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-16T06:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-12T09:45:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16102321\/A-Deep-Dive-into-the-Evolving-Pipeline.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novel Insight Into Acute Kidney Injury Treatment Pipeline","description":"The Acute Kidney Injury Therapies in the pipeline anticipated to launch in the next decade shall spur the AKI Market growth forward.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-pipeline","og_locale":"en_US","og_type":"article","og_title":"Novel Insight Into Acute Kidney Injury Treatment Pipeline","og_description":"The Acute Kidney Injury Therapies in the pipeline anticipated to launch in the next decade shall spur the AKI Market growth forward.","og_url":"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-pipeline","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-01-16T06:00:00+00:00","article_modified_time":"2025-02-12T09:45:47+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16102321\/A-Deep-Dive-into-the-Evolving-Pipeline.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-pipeline","url":"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-pipeline","name":"Novel Insight Into Acute Kidney Injury Treatment Pipeline","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-pipeline#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-pipeline#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16102321\/A-Deep-Dive-into-the-Evolving-Pipeline.png","datePublished":"2025-01-16T06:00:00+00:00","dateModified":"2025-02-12T09:45:47+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"The Acute Kidney Injury Therapies in the pipeline anticipated to launch in the next decade shall spur the AKI Market growth forward.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-pipeline"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/acute-kidney-injury-treatment-pipeline#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16102321\/A-Deep-Dive-into-the-Evolving-Pipeline.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16102321\/A-Deep-Dive-into-the-Evolving-Pipeline.png","width":466,"height":284,"caption":"A Deep Dive into the Evolving Pipeline"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/16102321\/A-Deep-Dive-into-the-Evolving-Pipeline-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Acute Kidney Injury Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Acute Kidney Injury Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Acute Kidney Injury Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">AKI<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Alloksys<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">AM Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Angion Biomedica<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Astellas Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Atox Bio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Exponential Biotherapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">MediBeacon<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Pharming Technologies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">QPI 1002<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Quark Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Ruconest<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Teprasiran<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Acute Kidney Injury Market<\/span>","<span class=\"advgb-post-tax-term\">Acute Kidney Injury Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Acute Kidney Injury Therapies<\/span>","<span class=\"advgb-post-tax-term\">AKI<\/span>","<span class=\"advgb-post-tax-term\">Alloksys<\/span>","<span class=\"advgb-post-tax-term\">AM Pharma<\/span>","<span class=\"advgb-post-tax-term\">Angion Biomedica<\/span>","<span class=\"advgb-post-tax-term\">Astellas Pharma<\/span>","<span class=\"advgb-post-tax-term\">Atox Bio<\/span>","<span class=\"advgb-post-tax-term\">Exponential Biotherapies<\/span>","<span class=\"advgb-post-tax-term\">MediBeacon<\/span>","<span class=\"advgb-post-tax-term\">Pharming Technologies<\/span>","<span class=\"advgb-post-tax-term\">QPI 1002<\/span>","<span class=\"advgb-post-tax-term\">Quark Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Ruconest<\/span>","<span class=\"advgb-post-tax-term\">Teprasiran<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Jan 16, 2025","modified":"Updated on Feb 12, 2025"},"absolute_dates_time":{"created":"Posted on Jan 16, 2025 11:30 am","modified":"Updated on Feb 12, 2025 3:15 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=10328"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10328\/revisions"}],"predecessor-version":[{"id":31046,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10328\/revisions\/31046"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30816"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=10328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=10328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=10328"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=10328"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=10328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}